Notably, IPF-LC patients exhibit lower frequencies of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations compared to LC patients, impacting treatment options and prognosis [56,121]. The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.